Robeco Institutional Asset Management B.V. lifted its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 18.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 146,163 shares of the biotechnology company’s stock after purchasing an additional 23,107 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.34% of United Therapeutics worth $79,204,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in UTHR. MBM Wealth Consultants LLC raised its holdings in United Therapeutics by 6.7% during the 3rd quarter. MBM Wealth Consultants LLC now owns 2,484 shares of the biotechnology company’s stock valued at $1,346,000 after buying an additional 157 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its position in United Therapeutics by 4.5% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 1,093 shares of the biotechnology company’s stock valued at $592,000 after buying an additional 47 shares during the period. Focused Alpha LLC bought a new stake in United Therapeutics in the 3rd quarter worth $538,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in United Therapeutics by 0.6% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,775 shares of the biotechnology company’s stock worth $2,588,000 after acquiring an additional 29 shares during the last quarter. Finally, Novem Group grew its holdings in United Therapeutics by 3.5% in the 3rd quarter. Novem Group now owns 2,035 shares of the biotechnology company’s stock worth $1,103,000 after acquiring an additional 69 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $516.06, for a total value of $4,902,570.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,432,054.58. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 401,528 shares of company stock valued at $208,069,526. 8.60% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
UTHR has been the topic of a number of analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 14th. UBS Group set a $725.00 price objective on shares of United Therapeutics in a research note on Monday. Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Royal Bank Of Canada raised their target price on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Finally, Leerink Partners raised their target price on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $651.21.
Check Out Our Latest Research Report on UTHR
United Therapeutics News Summary
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Analysts raised their outlook. Leerink Partners increased its price target for United Therapeutics to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus remains bullish, with a “Moderate Buy” rating and an average target near $650, implying further potential upside. Leerink Partners Raises Price Target
- Positive Sentiment: United Therapeutics expanded its xenograft capacity. The company opened its third designated pathogen-free xenograft production facility in Houston, Texas. The facility supports its longer-term strategy of developing genetically modified organs for transplantation and may strengthen future growth opportunities beyond its pulmonary hypertension drug franchise. Third Xenograft Production Facility
- Neutral Sentiment: Third-quarter earnings are approaching. United Therapeutics will report financial results before the market opens on November 4. The release could provide an important update on demand for Tyvaso and other pulmonary hypertension treatments, margins, and progress in organ manufacturing. Third-Quarter 2026 Earnings Announcement
- Negative Sentiment: Insider selling presents a modest cautionary signal. CEO Martine Rothblatt reported sales of 9,500 shares in transactions dated October 16 and October 19, reducing her position by about 2.84% in each filing. The company’s general counsel also sold shares under a trading plan. Because the sales appear relatively small compared with Rothblatt’s remaining stake and were conducted under planned arrangements, they do not necessarily indicate deteriorating business prospects.
United Therapeutics Stock Up 1.7%
Shares of United Therapeutics stock opened at $563.49 on Thursday. The business has a 50 day moving average of $515.71 and a 200 day moving average of $539.59. United Therapeutics Corporation has a 52 week low of $409.07 and a 52 week high of $609.35. The company has a market cap of $24.17 billion, a PE ratio of 20.16, a P/E/G ratio of 3.96 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.41 earnings per share. On average, research analysts anticipate that United Therapeutics Corporation will post 26.40 earnings per share for the current year.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
Read More
- Five stocks we like better than United Therapeutics
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
